Active Drug Surveillance Program of Ferriprox Use

Active Drug Surveillance Program of Ferriprox Use

Observational, open label, prospective, multi-center, post-marketing drug surveillance program.

A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients.

Main Inclusion Criteria:

• Patients who started Ferriprox therapy less than one month or are to initiate Ferriprox therapy at the time of enrolment into the program.

Main Exclusion Criteria:

• Patients treated with Ferriprox for more than one month prior to enrolment.